a cytokine expressed by bone marrow stromal cells, is a multipotential growth factor acting on early progenitor cells of most hematopoietic lineages. Therefore, we investigated the serum SCF levels in 74 HIV-infected persons without active secondary infection at different stages of HIV infection [Centers for Disease Control (CDC) stages A through Cl. Circulating SCF levels were determined by enzyme-linked immunosorbent assay and were found t o be significantly elevated in CDC stage A as compared with normal controls (7.18 f 1.94 nglmL v3.95 f 0.91 ng/mL, P = .04). However, in CDC groups B and C, SCF levels were lower than in CDC group A (3.29 f 0.75, P = .162, and 1.95 ? 0.39, P = .005, respectively). Serum levels greater than 1.8 nglmL were associated with a longer survival ( P = .0037) in 74 HIV
YTOPENIA IS A common complication of infection with the human immunodeficiency virus type 1 (HIV-1). In the course of their disease, more than 70% of HIVinfected patients develop anemia, frequently requiring transfusions.' Neutropenia, lymphopenia, and thrombocytopenia are also regularly seen, indicating that more than one hematopoietic lineage may be impaired. Dysfunction of the bone marrow stroma has been suggested as a possible mechanism.* One of the stroma-derived cytokines, stem cell factor (SCF), has recently been identified as a multipotential growth factor that acts on early hematopoietic progenitor cells of various lineages. It has strong synergistic effects with most of the lineage-restricted cytokines, including interleukin (1L)-3, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, erythropoietin, IL-6, and IL-7.3,4 This effect of SCF was also demonstrated in vitro on progenitor cells derived from HIV-infected pat i e n t~.~ Therefore, recombinant human (rh) SCF has been suggested as a candidate drug for use as adjunctive therapy in the treatment of HIV-related ~ytopenias.~ SCF levels during the clinical course in HIV infection have not yet been examined.
In this prospective study, serum SCF levels and clinical parameters of HIV-1 -seropositive individuals at different stages of their disease were investigated. A panel of cytokines was tested for their potency in regulating stromal SCF production.
C PATIENTS AND METHODS
Patients and collection of sera. In May 1992, 87 consecutive patients from the HIV Clinic of the Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine University of Duesseldorf Medical Center, Germany, were assessed, and peripheral blood was collected after informed consent was obtained. A total of 74 patients without signs of active secondary infection were enrolled in a prospective study and followed up clinically until July 1994. During a 3-month period, February to May 1993, 38 of these patients were seen a second time at the clinic, and a second blood type 1 (HIV-1)-seropositive patients monitored for up t o 114 weeks, suggesting that this cytokine may be directly associated with the disease course. A Cox proportional hazards model showed SCF t o be an independent prognostic factor for survival (risk ratio for death, 0.73; 95% confidence interval, 0.56 t o 0.95; P = .019). Serum SCF levels decreased on follow up in 24 of 38 patients or remained below 0.4 nglmL in 10 of 38 patients from whom a second blood sample was collected after a mean interval of 44 weeks. To determine potential regulatory factors of SCF expression by stromal cells, we exposed cultured fibroblasts t o various cytokines. Only interleukin-4 (IL-4) upregulated SCF mRNA. As IL-4 is modulated during early HIV disease, it may be a key regulator of SCF secretion. Further studies are required t o elucidate the mechanism of SCF action and regulation in patients with HIV infection.
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sample was drawn on all of them. For this subgroup of patients, the mean follow-up duration until the second blood sample was 44 weeks (range, 36 to S2 weeks). At the time of blood sampling, all patients were free from signs and symptoms of active illness. Thirteen patients with active illness during the enrollment period were compared with the group of 74 patients without apparent infection. In the absence of disease-specific clinical parameters, temperature above 38.SoC, persistent severe diarrhea, and coughing were used as criteria of an active infection. To ascertain whether SCF could be produced locally at the site of infection, simultaneous serum and cerebrospinal fluid (CSF) samples were obtained after informed consent from 21 additional patients with known or suspected brain lesions. In four patients, second and third spinal taps were collected after an interval of 6 days to 6 months. Serum SCF levels from 46 healthy blood donors served as controls. All patients were classified according to the 1993 Centers for Disease Control (CDC) staging system6 The serum was centrifuged directly after clotting. CSF and serum were frozen in aliquots at -80°C.
Determination of serum SCF levels. SCF concentration in serum samples was determined by a sandwich enzyme-linked immunosorbent assay (ELISA) using murine monoclonal antibodies (MoAbs) raised by one of us (T.P.) against rhSCF. Anti-SCF MoAb 1OES (IgA) was coated on 96-well microtiter plates (Immunosorp; Nunc, Roskilde, Denmark). Dilutions of serum samples (100 pL per well) in phosphate-buffered saline (PBS), 0.1 mglmL bovine serum albu- min (BSA), 0.02% NaN, were incubated for 2 hours at room temperature. Bound SCF was detected by MoAbs 5D8 and 8G11 (both IgGI) and an isotype-specific antimouse IgG immunoglobulin conjugated with alkaline phosphatase (Sigma, Deisenhofen, Germany). Between the incubation steps (2 hours each), the plates were washed three times with PBS, 0.05% Tween 20. The final washes before incubation with substrate were performed with Tris-buffered saline. The immunoreaction was visualized by p-nitrophenol substrate (Sigma) and read at 405 nm. All samples were tested in duplicate. SCF levels were calculated from a standard curve using rhSCF standard concentrations ranging from 0.05 to 12.8 ng/mL. Samples with SCF levels above 10 ng/mL were diluted and retested. The data were linearized using lognog transformation. The sensitivity of this assay was less than 0.4 ng/mL.
Stimulation ofjbroblasrs by As a model for stromal cells, human foreskin fibroblasts were explanted and grown to subconfluence in RPM1 1640, 10% fetal calf serum (FCS; GIBCO, Eggenstein, Germany). A panel of cytokines including IL-l, IL-2, IL-3, IL-4, IL-6, IL-7, tumor necrosis factor (TNF) a, and y-interferon was tested for the ability to upregulate SCF production. Recombinant human IL-4 provided by Dr L. Souza (Amgen, Thousand Oaks, CA) was added in a concentration of 100 ng/mL at 0.5, 1, 1.5, 2, 4, and 6 hours before harvesting. Cellular RNA was prepared by the guanidinium isothiocyanate/cesium chloride method.' The RNA was separated on a 1% formaldehyde agarose gel (15 pg per lane) and blotted onto nylon membranes (Hybond-N; Amersham, Braunschweig, Germany). The filters were hybridized for 16 hours at 58°C in the presence of formamide with a [32P]cytidine triphosphate (CTP)-labeled SCF antisense transcription probe generated from a pGEM-3 vector with a 0.45-kbp SCF cDNA insert by SP6 DNA polymerase after linearization of the plasmid with Sac I. The plasmid was provided by Dr K. Zsebo, Amgen. Unbound radiolabeled probe was removed by several washes with 0.1 X standard sodium citrate (SSC); a final wash was performed at 65°C. The membranes were then autoradiographed for 3 days at -80°C using Cronex films (Dupont, Neu-Isenburg, Germany).
Sruristical analysis. Differences between patient groups were calculated using the Mann-Whitney U test for independent data or Wilcoxon signed rank test for dependent data. Correlation analysis was performed by the method of Spearman. Analysis of variance, covariance, and multivariate analysis were performed by a general linear model (GLM) using log-transformed SCF values. For lifetable estimates, the Kaplan-Meier analysis and the log-rank test were used. Multivariate analysis of the survival data and covariates was performed using the Cox proportional hazards model. A f value less than .OS was considered significant. SCF levels and the other interval scaled data are expressed as means 2 standard error of the mean (SEM) if not indicated otherwise. For computation, the SAS System (SAS Institute, Cary, NC) was used.
RESULTS

Patients.
Seventy-four (85%) of the screened patients were free of signs or symptoms of active infection other than HIV and constitute the study cohort. Forty-two patients (57%) were classified as CDC stage C, ie, having a history of at least one AIDS-defining disease ( Table 1) . As these patients attend the clinic more frequently than patients at earlier stages of HIV disease, they are overrepresented in our sample. The majority of our collective were German homosexual males (79%). Decreasing CD4' lymphocyte counts as the most important marker of HIV infection indicate progression of the disease (Table 2) . Patients with less than 500 CD4' cells per microliter were usually treated with 
Epidemiologic data of 74 consecutive patients enrolled in the study. Patients were free from active infection other than HIV infection. They are classified according to the 1993 staging system of the CDC. Group A includes asymptomatic patients with or without persistent lymphadenopathy; group C, patients with a history of one or more AIDSdefining diseases; and group B, patients in neither group A nor group C. The predominant risk group in our collective are men with homosexual or bisexual behavior. Among the six female patients, there are two former intravenous drug abusers, two recipients of infected blood products, and two with unclear infection route, most probably heterosexual contact. All but three patients were white zidovudine (ZDV) as antiretroviral therapy. This drug is known to have myelosuppressive activity. In the present study, the proportion of patients on ZDV did not differ significantly among the three CDC subgroups. A total of 10 other patients received potentially myelosuppressive medications: seven were treated for Kaposi's sarcoma with liposomal doxorubicin, two received low-dose co-trimoxazol prophylaxis for Pneumocystis carinii pneumonia, and one was treated with prophylactic acyclovir for recurrent zoster.
Normal serum SCF levels. Controls were 46 healthy blood donors. The mean SCF level was 3.95 ng/mL [95% confidence interval (CI95), 2.12 to 5.78 ng/mL; SEM, 0.91 ng/mL). The range of SCF levels was less than 0.4 ng/mL to 27.64 ng/mL. No correlation with white blood cell (WBC) and platelet counts, or levels of hemoglobin, serum transaminases, bilirubin, lactate dehydrogenase (LDH), urea or total serum protein was observed.
Differences in serum SCF levels between CDC groups. The mean serum SCF level in all 74 HIV-l -seropositive patients without active infection was comparable with the mean level in the controls (3.32 f 0.53 g/mL v 3.95 2 0.91 ng/mL). The levels ranged from less than 0.4 ng/mL to 26.38 ng/mL. However, when samples were stratified according to the CDC classification, clear differences became obvious (Fig 1) . Asymptomatic patients (CDC group A) exhibited a significantly elevated mean SCF level (7.18 f 1.94 ng/mL; P = .04 v controls). SCF levels in CDC group B (3.29 2 0.75 ng/mL) and CDC group C (1.95 2 0.39 ng/mL) were lower than the mean level in the controls, although the differ- Data are means -t SEM or frequencies. ZDV therapy (in general, 250 mg twice a day) was initiated in patients with CD4' lymphocyte counts less than 500/pL. Chemotherapy indicates liposomal doxorubicin (20 mg/kg body weight every 2 to 4 weeks) for treatment of Kaposi's sarcoma. All of these 74 patients maintained leukocyte counts >2,OOO/pL and, therefore, did not receive recombinant G-CSF. Other myelosuppressive therapy includes prophylactic therapy for recurrent zoster with acyclovir (one case) and prophylaxis for fneumocystis carinii pneumonia with co-trimoxazole (two cases).
ences were not significant. Compared with group C, groups A and B showed significantly higher values ( P = ,005 and .037, respectively). Analysis of variance showed the CDC stage as the only significant ( P = ,011) independent main effect on SCF levels among all tested variables (age, sex, risk group, concurrent therapy, and hematologic parameters).
Decrease in serum SCF levels during the clinical course of HIV infection. In 38 patients, a second blood sample was collected at intervals of 36 to 52 weeks after the first sample (mean, 44 weeks). In all but four patients, the SCF levels decreased (n = 24) or remained below 0.4 ng/mL (n = 10). Mean values of the first sample were significantly higher compared with the second samples (3.73 ? 0.68 ng/ mL and 2.54 2 0.58 ng/mL, respectively; P = ,0003; Fig 2). None of the patients with first-sample serum levels lower than 0.4 ng/mL (n = 10) was found to have an SCF level above this level in the second sample. A concomitant decrease in the CD4+ cell count (231/pL v 176/pL; P = .0001) and platelet count (175/nL v 167/nL; P = .02) and an increase in relative CD8+ lymphocyte numbers (57% v 63%; P = .002) were also found. During the observation period, no significant differences between the hemoglobin levels (13.6 g/dL v 13.8 g/dL) or leukocyte counts (4.21/nL v 4.22/ nL) could be detected (Fig 3) .
Correlation of serum SCF levels, hemoglobin concentration, and T helper-cell counts.
Serum SCF levels were found to correlate significantly with hemoglobin concentrations ( r = .401; P = .001) and absolute CD4' cell counts ( r = .275; P = .042), as well as with CD4+:CD8+ ratios ( r = .275; P = .047). A positive correlation with hemoglobin was also significant in CDC group C alone (n = 34, r = .432, P = .01). There was no significant correlation with total leukocyte, neutrophil, lymphocyte, or platelet counts, p24 antigen concentrations, or CD8' lymphocyte counts. Similar observations were made when only patients of CDC group C were analyzed.
Association of serum levels below 1.8 n g h L with reduced life expectancy. Survival estimates were determined by Kaplan-Meier analysis. The patients were stratified into two groups of equal size. Patients with serum levels below 1.8 ng/mL (n = 37) were compared with patients with SCF levels 2 1.8 ng/mL (n = 37). Within a follow-up period of up to 114 weeks, 34 of 74 patients died (22 in the first group v 12 in the second group). As shown in Fig 4 , survival of patients with serum levels higher than 1.8 ng/mL was significantly longer ( P = .0037). A Cox proportional hazards model with stepwise multiple regression was used to determine the influence of the individual parameters SCF level (log-transformed), sex, age, risk group, concurrent medication, disease stage, CD4' and CD8+ lymphocyte subtypes, and hematologic parameters. After adjusting the model for sex, age, risk group, and concurrent medication, the re- maining variables were entered into the model. SCF levels [risk ratio for death (RR), 0.73; CI95, 0.56 to 0.95; P = .019], relative CD4+ cell count (RR, 0.86; CI95, 0.78 to 0.94; P = .002), and ZDV therapy (RR, 0.39; CI95, 0.16 to 0.95; P = .039) had a positive independent effect on overall survival, while platelet counts (RR, 1.006; CI95, 1.001 to 1.01 1; P = .026) showed a slight negative effect on survival. In this model, there was no significant additional effect of sex, age, risk group, concurrent medication other than ZDV, disease stage, CD8+ lymphocyte count, WBC count, or hemoglobin concentration on survival.
SCF levels under concurrent therapy. Among the 74 patients without active infection enrolled in the study, 33 patients received ZDV, seven patients received liposomal doxorubicin, and three patients received other myelosuppressive therapy. There was no significant difference in the proportion of patients receiving ZDV among the CDC groups. Analysis of variance showed no significant influence of the kind of therapy on SCF levels.
SCF levels in patients with active infection. Thirteen patients had active secondary infections. Four patients had elevated temperatures of unknown origin above 38.5"C, two patients had active hepatitis C, three patients had active hepatitis B, three patients had meningitis (staphylococcal, cryptococcal, and mycobacterial), and one patient had persistant coughing with elevated temperature. The highest SCF level was 63 ng/mL in a female patient with active hepatitis C and a history of intravenous drug abuse. Patients in CDC group C (n = 9) had SCF levels between less than 0.4 ng/ mL and 5.5 ng/mL, with a mean of 3.28 ng/mL 2 0.58 SEM. As shown in Fig 5, the mean SCF level in this subset was significantly higher ( P = .019) compared with the patients without apparent active disease in CDC group C (n = 42; mean SCF level, 1.95 ng/mL). There was no difference in CD4+ cell counts or any hematologic parameter between the two groups, except that hemoglobin levels were significantly lower in the group with active infection.
SCF levels in CSF. Twenty-nine CSF samples from 21 patients with known or suspected cerebral diseases were tested. All but one of the SCF levels in the CSF of these patients were below 0.4 ng/mL. Fourteen patients had serum SCF levels higher than 0.4 ng/mL. Even in one case of bacterial meningitis with a CSF leukocyte count greater than 21,OOO/pL, the SCF level remained less than 0.4 ng/mL, whereas serum SCF was 3.06 ng/mL. In contrast, in one patient, the SCF level was as high as 1.18 ng/mL in the CSF but was 0.5 ng/mL in the serum.
IL-4 upregulates SCF mRNA expression in jibrohlasts.
A panel of cytokines was tested for their ability to upregulate SCF production in human fibroblasts. Only exposure of cultured human fibroblasts to rhIL-4 resulted in an upregulation of SCF mRNA levels (Fig 6) . This increase in SCF mRNA was maximal after 0.5 to 1 hour. The mRNA levels returned to baseline levels after 6 hours.
DISCUSSION
Cytopenia is a common problem in HIV-infected individuals during the course of their disease. The degree of cytopenia often reflects the severity of the disease itself. The roles of various lineage-restricted hematopoietic growth factors, such as erythropoietin' and granulocyte colony-stimulating factor: have already been investigated, and some of these growth factors have been successfully introduced as therapy for HIV-related anemia and neutropenia. Several investigators have suggested that HIV-associated cytopenia may be caused by stromal cell defects of the bone marrow.' These stromal cells are a major source of both the soluble and membrane-associated forms of SCF.'" SCF has recently been found to be a potent synergistic stimulator of progenitor cells of several lineages of the hematopoietic and lymphopoietic system.'.4 At present, there is no information available regarding the endogenous levels of SCF and its role in the regulation of progenitor cell proliferation and maturation in HIV-infected patients.
Decrease in SCF levels with progression of HIV disease. At later stages of the HIV disease, cytopenia becomes clinically increasingly significant. Therefore, one would expect endogenous SCF levels to be upregulated with disease progression. However, when sera from 74 individuals at different stages of the HIV infection were tested, patients in CDC group C had slightly reduced SCF levels compared with healthy control subjects and significantly lower levels compared with earlier disease stages (Fig l) . Concomitantly, SCF levels declined with duration of disease in individuals who were followed-up longitudinally over a mean period of 44 weeks (Fig 2) . In contrast, endogenous SCF levels were significantly elevated in HIV-infected asymptomatic patients (CDC group A , Fig l) , a clinical situation where cytopenia is very uncommon. We also found a positive correlation between SCF levels and blood hemoglobin concentrations, but not with leukocyte or platelet counts. Therefore, SCF levels do not seem to be directly upregulated by cytopenia or low hemoglobin concentration. A similar situation has already been described in patients with aplastic anemias, where serum SCF levels were also not found to be directly upregulated by peripheral blood hemoglobin concentration." As cell numbers in the peripheral blood do not give reliable information about the whole hematopoietic cell pool and turnover of certain lineages, a possible feedback mechanism might be undetectable by these parameters.
Correlation of serum SCF levels with survival. In our study, serum SCF levels were found to correlate significantly with overall survival (P = .019). HIV-infected patients with SCF levels higher than 1.8 ng/mL survived significantly longer than those with lower levels ( P = ,0037; Fig 4) . Therefore, we hypothesize that the association of lower SCF levels with reduced survival may be the consequence of a relative lack of this cytokine in a pathologic situation where the progenitor cell population is already impaired by the HIV infection itself andor myelosuppressive substances. In fact, many patients, usually those in an advanced stage of disease, receive multiple medications, some of which have myelosuppressive potential. In our collective, we found no evidence by multivariate analysis that the concurrent therapy has any influence on SCF levels. However, these data may be biased, as the patient subgroups in this study are not matched with regard to the kind of medication they were receiving.
SCF levels in secondary infections. SCF levels are elevated in patients with secondary infections (Fig 5) . In contrast, SCF levels are not detectable in CSF of patients with cerebral lesions irrespective of their serum SCF levels. Therefore, the site of SCF production seems not to be always identical with the site of infection.
Factors regulating SCF expression. The mechanisms leading to changes in serum SCF levels in individuals with HIV infection are unknown. SCF levels are low in later stages of the disease and elevated in asymptomatic patients and patients with secondary infections (Fig 5) . Interleukins are important mediators and regulators during infection. Many of them are modulated during the course of HIV infection. In vitro, we found IL-4 to be the only cytokine among those tested that was able to induce SCF expression in stromal cells, especially endothelial cells and fibroblasts (Fig 6) .
This increase seemed to occur via stabilization of SCF mRNA rather than through increased transcription." Therefore, the changes in SCF levels in vivo could be the result of modulated IL-4 production during the HIV infection. In the clinically latent stage of the disease, CD4' cells have a large burden of actively replicating HIV viruses." Some investigators suggest that infected T helper cells in vitro exhibit a predominance of subpopulations producing IL-4 in early disease stage^,'^"^ although this model is not unchallenged.'' During disease progression, IL-4 production by CD4' cells may be increasingly impaired.lx~19 This would be compatible with the hypothesis of CD4' cells regulating SCF levels in HIV infection. Additional in vitro studies are necessary to elucidate whether IL-4 acts as an inducer of SCF in bone marrow stromal cells from HIV-infected individuals.
Potential role of SCF in HIV infection. The role of SCF in the pathomechanism of HIV infection remains to be elucidated. Counteraction of cytopenia may be one of the possible effects. The human SCF gene has been cloned, and the recombinant protein has been expressed in Escherichia coli.2o In vitro, SCF was shown to have no effect on HIV replication in monocytes and lymphocytes, and recombinant SCF has, therefore, been suggested as a potential drug for treatment of HIV-related cytopenia.' In addition, it was shown in previous in vitro studies that the IC50 of the myelosuppressive substance ZDV was increased dramatically by rhSCF, suggesting that the antihematopoietic effects of this substance can be partially overcome by SCF.'
The use of exogenously administered recombinant growth factors can still be effective if the level of the endogenous factor is not reduced. An example is severe congenital neutropenia, which responds dramatically to rhG-CSF even though these patients have normal or elevated serum levels of G-CSF."."
In conclusion, our results show that SCF is upregulated during early stages of HIV infection and decreases with disease progression. Serum SCF levels are correlated with prolonged survival. This observation may point to the possible clinical use of rhSCF in patients with HIV infection.
